All In Biotech

Drug Trial Radar · NCT03697109

A Study of the Efficacy and Safety of Relacorilant in Patients With Endogenous Cushing Syndrome

Glucocorticoid Receptor Antagonism in the Treatment of Cushing Syndrome (GRACE): A Phase 3, Double-Blind, Placebo-Controlled, Randomized-Withdrawal Study of the Efficacy and Safety of Relacorilant

Last checked: Nov 19, 2026Latest source record: Jul 16, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 152 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

152

Actual

Start

Nov 15, 2018

Primary completion

Apr 8, 2024

Study completion Apr 15, 2024

Sponsor

Lead sponsor
Corcept TherapeuticsIndustry
Sponsor type
Industry
First posted
Oct 5, 2018

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 80 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a Phase 3, double-blind, placebo-controlled, randomized-withdrawal study to assess the efficacy, safety and pharmacokinetics (PK) of relacorilant in patients with endogenous Cushing syndrome and concurrent type 2 diabetes mellitus/impaired glucose tolerance (DM/IGT) and/or uncontrolled hypertension (HTN).

Conditions

  • Cushing Syndrome

Interventions

  • RelacorilantDrug

    Relacorilant is supplied as 100 mg capsules for oral dosing.

  • PlaceboOther

    Placebo matched to study drug

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Patients With Loss of Response With Respect to Hypertension During the RW Phase.Time frame: Week 22 (end of OL Phase) and Week 36 (Week 12 of RW Phase)
  2. Number of Patients With 1 or More Treatment-emergent Adverse Events (TEAEs) as Graded by CTCAE v5.0.Time frame: OL Phase: Up to 22 weeks; RW Phase: up to 18 weeks after completion of the OL Phase

Locations

64 sites in 11 countries. Site status is shown where the registry gives one.

  • Site 21

    Phoenix, Arizona

  • Site 36

    Los Angeles, California

  • Site 68

    Torrance, California

  • Site 10

    Miami, Florida

  • Site 14

    Atlanta, Georgia

  • Site 41

    Chicago, Illinois

  • Site 7

    Indianapolis, Indiana

  • Site 2

    Metairie, Louisiana

  • Site 45

    Baltimore, Maryland

  • Site 46

    Boston, Massachusetts

  • Site 20

    Ann Arbor, Michigan

  • Site 4

    Jackson, Mississippi

  • Site 13

    St Louis, Missouri

  • Site 53

    Omaha, Nebraska

  • Site 72

    Reno, Nevada

  • Site 8

    Albany, New York

  • Site 6

    Jamaica, New York

  • Site 57

    New York, New York

  • Site 35

    New York, New York

  • Site 39

    New York, New York

  • Site 1

    Wilmington, North Carolina

  • Site 17

    Columbus, Ohio

  • Site 11

    Oklahoma City, Oklahoma

  • Site 62

    Philadelphia, Pennsylvania

  • Site 19

    Pittsburgh, Pennsylvania

  • Site 71

    Pittsburgh, Pennsylvania

  • Site 5

    Summerville, South Carolina

  • Site 51

    Dallas, Texas

  • Site 3

    El Paso, Texas

  • Site 65

    Houston, Texas

  • Site 56

    Shavano Park, Texas

  • Site 31

    Everett, Washington

  • Site 47

    Vienna, Austria

  • Site 27

    Sofia, Bulgaria

  • Site 58

    Montreal, Canada

  • Site 70

    Halifax, Nova Scotia, Canada

  • Site 54

    München, Germany

  • Site 49

    Würzburg, Germany

  • Site 30

    Jerusalem, Israel

  • Site 29

    Kfar Saba, Israel

Showing 40 of 64 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.